Pharmaceutical Detailing Elasticities: A Meta-Analysis - Innovation and Marketing in the Pharmaceutical Industry - page 544

Andersson F, Hertzman P (1993) Effective patent life of drugs in Sweden—a comparison with
international studies. Managerial Decis Econ 14:53-63
Andrews RL, Franke GR (1991) The determinants of cigarette consumption: a meta-analysis.
J Public Policy Mark 10(Spring):81-100
Assmus G, Farley JU, Lehmann DR (1984) How advertising affects sales: a meta analysis of
econometric results. J Mark Res 21(1):65-74
Baldwin H (2011) Big change at big pharma. Selling Power, May/June, Cover Story. Available at
http://www.sellingpower.com/content/article.php?a=9459#topArticlePages
Berenson A (2006) New chief at Pfi zer will reduce sales force. The New York Times,
29 Nov 2006
Berndt ER, Bui LT, Reiley DH, Urban GL (1995) Information, marketing, and pricing in the U.S.
antiulcer drug market. Am Econ Rev Pap Proc 85:100-105
Berndt ER, Pindyck RS, Azoulay P (2003) Consumption externalities and diffusion in pharmaceu-
tical markets: antiulcer drugs. J Ind Econ 101(2):243-270
Bhatia T, Le W (2011) Identifying peer-to-peer effects using patient movement data. Int J Res
Mark 28(1):51-61
Bijmolt THA, Pieters RGM (2001) Meta-analysis in marketing when studies contain multiple
measurements. Mark Lett 12(2):157-169
Bijmolt THA, van Heerde HJ, Pieters RGM (2005) New empirical generalizations on the determi-
nants of price elasticity. J Mark Res 42:121-156
Campbell S (2009) Promotional spending for prescription drugs, economic and budget issue brief,
Congressional Budget Offi ce, December. Available at http://www.cbo.gov/
Cegedim-SK&A (2011) 2010 U.S. Pharma Company promotion Spending, January. Available at
www.forums.pharma-mkting.com/attachment.php?attachmentid=154&d
Chintagunta PK, Desiraju R (2005) Strategic pricing and detailing behavior in international
markets. Mark Sci 24(1):67-80
Clarke K (2005) The phantom menace: omitted variable bias in econometric research. Confl
Manag Peace Sci 22:341-352
Dave D, Saffer H (2010) The impact of direct-to-consumer advertising on pharmaceutical prices
and demand, working paper 15969. National Bureau of Economic Research. Available at http://
www.nber.org/papers/w15969
Derrick R (2011) Trends in promotion. Cegedim strategic data, May. Available at http://
www.pmlive.com/find_an_article/allarticles/categories/General/2011/may_2011/features/
trends_in_promotion
Donohue J, Berndt ER (2004) Effects of direct-to-consumer advertising on medication choice: the
case of antidepressants. J Public Policy Mark 23(2):115-127
Donohue JM, Cevasco M, Rosenthal MB (2007) A decade of direct-to-consumer advertising of
prescription drugs. N Engl J Med 357(7):673-681
Dorfman R, Steiner PO (1954) Optimal advertising and optimal quality. Am Econ Rev 44:
826-836
Elling ME, Fogle HJ, McKhann CS, Simon C (2002) Making more of pharma's sales force.
McKinsey Quarterly (3):86-95
Farley JU, Lehmann DR (1994) Cross-national laws and differences in market response. Manag
Sci 40:111-122
Farley JU, Lehmann DR, Sawyer AG (1995) Empirical marketing generalization using meta-
analysis. Mark Sci 14(3):G36-G46
Farley JU, Lehmann DR, Mann LH (1998) Designing the next study for maximum impact. J Mark
Res 35:496-501
Fischer M, Albers S (2010) Patient- or physician-oriented marketing: what drives primary demand
for prescription drugs. J Mark Res 47(1):103-121
Fischer M, Albers S, Wagner N, Frie M (2011) Patient- or physician-oriented marketing: what
drives primary demand for prescription drugs?. J Mark Res 47:103-121
Gagnon M-A, Lexchin J (2008) The cost of pushing pills: a new estimate of pharmaceutical
promotion expenditures in the United States. PLoS Med 5(1):29-33